Axitinib User Reviews & Ratings
Brand names: Inlyta
Axitinib has an average rating of 5.5 out of 10 from a total of 2 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 50% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Renal Cell Carcinoma | 2 reviews for Renal Cell Carcinoma | 23 medications |
- Qui...
- Taken for less than 1 month
- September 5, 2019
For Renal Cell Carcinoma "So far, axitinib is making me vomit more."
Are you taking this medicine?
Your review helps others make informed decisions.Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about axitinib
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Axitinib for Renal Cell Carcinoma "Husband is taking Inlyta now for about 4 months. Visible tumors have reduced in size by almost half. Side effects that have shown up are endocrine in nature: adrenal glands reduced production, feet glands for corns and bone spurs, mucus membrane in sinus, loss of salivation production. Greater thirst is prevalent and additional fluid for intake to maintain hydration. Due to this, 2 additional pills introduced: Levothyroxine for thyroid and cortisone type (??name) for adrenal gland function. Specialists now are: oncologist, endocrinologist, podiatrist, nephrologist (for the 1 remaining kidney), and his primary doctor."